Novo Nordisk A/S
CSE:NOVO B

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
CSE:NOVO B
Watchlist
Price: 455.9 DKK 2.62% Market Closed
Market Cap: 2T DKK

Relative Value

The Relative Value of one NOVO B stock under the Base Case scenario is 695 DKK. Compared to the current market price of 455.9 DKK, Novo Nordisk A/S is Undervalued by 34%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NOVO B Relative Value
Base Case
695 DKK
Undervaluation 34%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
74
vs Industry
18
Median 3Y
10.9
Median 5Y
9.9
Industry
2.4
Forward
5.8
vs History
82
vs Industry
21
Median 3Y
34.9
Median 5Y
29.4
Industry
20.3
Forward
16.8
vs History
77
vs Industry
23
Median 3Y
25.1
Median 5Y
23.1
Industry
15.6
vs History
96
vs Industry
24
Median 3Y
32.9
Median 5Y
24.5
Industry
23.1
vs History
82
vs Industry
3
Median 3Y
24.2
Median 5Y
20.2
Industry
2
vs History
74
vs Industry
16
Median 3Y
11
Median 5Y
9.9
Industry
2.5
Forward
6
vs History
74
vs Industry
22
Median 3Y
13.1
Median 5Y
11.9
Industry
4.8
vs History
87
vs Industry
25
Median 3Y
23.3
Median 5Y
21.4
Industry
12.5
Forward
11.7
vs History
80
vs Industry
25
Median 3Y
25.6
Median 5Y
23.4
Industry
15.7
Forward
13.1
vs History
76
vs Industry
23
Median 3Y
25
Median 5Y
23.1
Industry
14.1
vs History
52
vs Industry
15
Median 3Y
33.1
Median 5Y
29.7
Industry
17.6
vs History
96
vs Industry
13
Median 3Y
9.6
Median 5Y
8.7
Industry
1.8

Multiples Across Competitors

NOVO B Competitors Multiples
Novo Nordisk A/S Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 7 20 13.2 15
US
Eli Lilly and Co
NYSE:LLY
780.6B USD 15.9 70.3 37.7 41.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
375.6B USD 4.2 17.2 12.6 16.5
CH
Roche Holding AG
SIX:ROG
216.7B CHF 3.6 26.2 9.8 11.5
CH
Novartis AG
SIX:NOVN
184.6B CHF 4.2 17.4 10.3 13.7
UK
AstraZeneca PLC
LSE:AZN
166.7B GBP 4 28.5 130.9 197.3
US
Merck & Co Inc
NYSE:MRK
210.2B USD 3.3 12.1 8.6 10.4
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
122.8B EUR 1.3 9.7 5.3 6.2
US
Pfizer Inc
NYSE:PFE
137.1B USD 2.2 17.4 7.5 10.7
P/E Multiple
Earnings Growth PEG
DK
Novo Nordisk A/S
CSE:NOVO B
Average P/E: 24.3
20
18%
1.1
US
Eli Lilly and Co
NYSE:LLY
70.3
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.2
27%
0.6
CH
Roche Holding AG
SIX:ROG
26.2
32%
0.8
CH
Novartis AG
SIX:NOVN
17.4
17%
1
UK
AstraZeneca PLC
LSE:AZN
28.5
36%
0.8
US
Merck & Co Inc
NYSE:MRK
12.1
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.7
28%
0.3
US
Pfizer Inc
NYSE:PFE
17.4
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
Novo Nordisk A/S
CSE:NOVO B
Average EV/EBITDA: 394.9
13.2
14%
0.9
US
Eli Lilly and Co
NYSE:LLY
37.7
31%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.6
8%
1.6
CH
Roche Holding AG
SIX:ROG
9.8
6%
1.6
CH
Novartis AG
SIX:NOVN
10.3
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
130.9
9%
14.5
US
Merck & Co Inc
NYSE:MRK
8.6
9%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.3
8%
0.7
US
Pfizer Inc
NYSE:PFE
7.5
2%
3.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
Novo Nordisk A/S
CSE:NOVO B
Average EV/EBIT: 1 698.2
15
14%
1.1
US
Eli Lilly and Co
NYSE:LLY
41.2
33%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.5
13%
1.3
CH
Roche Holding AG
SIX:ROG
11.5
6%
1.9
CH
Novartis AG
SIX:NOVN
13.7
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.3
21%
9.4
US
Merck & Co Inc
NYSE:MRK
10.4
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
6.2
14%
0.4
US
Pfizer Inc
NYSE:PFE
10.7
11%
1